Gennao Bio Appoints Chris Duke as Chief Operating Officer and Julie Hambleton, M.D., to Board of Directors HOPEWELL, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the...

Gennao Bio Closes $40 Million Series A Financing to Develop Pipeline of Targeted Nucleic Acid Therapeutics ~ Financing Co-led by OrbiMed and Logos Capital to Support Advancement of Proprietary Gene Monoclonal Antibody Platform (GMAB) ~ ~ Stephen Squinto, Ph.D., Appointed Chief Executive Officer and...